272 related articles for article (PubMed ID: 23227588)
1. [Personalized treatment in non-small cell lung cancer].
Campos-Parra AD; Cruz-Rico G; Arrieta O
Rev Invest Clin; 2012; 64(4):377-86. PubMed ID: 23227588
[No Abstract] [Full Text] [Related]
2. [Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):398-400. PubMed ID: 22883466
[No Abstract] [Full Text] [Related]
3. [Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No].
Girard N
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S96-9. PubMed ID: 26118885
[TBL] [Abstract][Full Text] [Related]
4. Targeted treatment tested as potential cancer cure.
Hayden EC
Nature; 2011 Nov; 479(7373):281. PubMed ID: 22094668
[No Abstract] [Full Text] [Related]
5. Gefitinib in the treatment of advanced non-small-cell lung cancer.
Reck M
Expert Rev Anticancer Ther; 2009 Apr; 9(4):401-12. PubMed ID: 19374595
[TBL] [Abstract][Full Text] [Related]
6. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene].
Francoz S; Dubus P
Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418
[No Abstract] [Full Text] [Related]
7. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
[TBL] [Abstract][Full Text] [Related]
8. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
[TBL] [Abstract][Full Text] [Related]
9. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
Gridelli C
Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
[No Abstract] [Full Text] [Related]
10. More than just an oncogene translocation and a kinase inhibitor: Kevin's story.
Costa DB
J Clin Oncol; 2012 Jan; 30(1):110-2. PubMed ID: 22067391
[No Abstract] [Full Text] [Related]
11. Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Santarpia M; Altavilla G; Salazar MF; Magri I; Pettineo G; Benecchi S; Rosell R
Expert Rev Respir Med; 2011 Jun; 5(3):413-24. PubMed ID: 21702662
[TBL] [Abstract][Full Text] [Related]
12. Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Friedrich MJ
J Natl Cancer Inst; 2009 Aug; 101(15):1039-41. PubMed ID: 19638503
[No Abstract] [Full Text] [Related]
13. Directed therapies in lung cancer: new hope?
Parente Lamelas I; Abal Arca J; Fírvida Pérez JL
Arch Bronconeumol; 2012 Oct; 48(10):367-71. PubMed ID: 22551924
[TBL] [Abstract][Full Text] [Related]
14. [New era in cancer therapy. Gefitinib: small molecule--strong action].
Arnheim K
MMW Fortschr Med; 2004 Nov; 146(47):70-1. PubMed ID: 15624666
[No Abstract] [Full Text] [Related]
15. [Is it possible to treat bronchial carcinoma without chemotherapy?].
Pujol JL
Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S23-10S26. PubMed ID: 17127957
[No Abstract] [Full Text] [Related]
16. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
[No Abstract] [Full Text] [Related]
17. Personalized medicine for non-small-cell lung cancer.
Mok TS; Zhou Q; Leung L; Loong HH
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1601-11. PubMed ID: 20942631
[TBL] [Abstract][Full Text] [Related]
18. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Reddy GK
Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
[No Abstract] [Full Text] [Related]
19. Experience with erlotinib in lung adenocarcinoma harboring a coexisting KIF5B-RET fusion gene and EGFR mutation: report of a rare case.
Hirai F; Takenoyama M; Taguchi K; Toyozawa R; Inamasu E; Toyokawa G; Yoshida T; Shiraishi Y; Takenaka T; Yamaguchi M; Ushijima C; Seto T; Takeo S; Ichinose Y
J Thorac Oncol; 2014 May; 9(5):e37-9. PubMed ID: 24722163
[No Abstract] [Full Text] [Related]
20. ALK, lung cancer, and personalized therapy: portent of the future?
Garber K
J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
[No Abstract] [Full Text] [Related]
[Next] [New Search]